Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
Candida albicans is the leading fungal pathogen of humans, causing life-threatening disease in immunocompromised individuals. Treatment of candidiasis is hampered by the limited number of antifungal drugs whose efficacy is compromised by host toxicity, fungistatic activity, and the emergence of drug resistance. We previously established that the molecular chaperone Hsp90, which regulates the form and function of diverse client proteins, potentiates resistance to the azoles in C. albicans and in the model yeast Saccharomyces cerevisiae. Genetic studies in S. cerevisiae revealed that Hsp90's role in azole resistance is to enable crucial cellular responses to the membrane stress exerted by azoles via the client protein calcineurin. Here, we demonstrate that Hsp90 governs cellular circuitry required for resistance to the only new class of antifungals to reach the clinic in decades, the echinocandins, which inhibit biosynthesis of a critical component of the fungal cell wall. Pharmacological or genetic impairment of Hsp90 function reduced tolerance of C. albicans laboratory strains and resistance of clinical isolates to the echinocandins and created a fungicidal combination. Compromising calcineurin function phenocopied compromising Hsp90 function. We established that calcineurin is an Hsp90 client protein in C. albicans: reciprocal co-immunoprecipitation validated physical interaction; Hsp90 inhibition blocked calcineurin activation; and calcineurin levels were depleted upon genetic reduction of Hsp90. The downstream effector of calcineurin, Crz1, played a partial role in mediating calcineurin-dependent stress responses activated by echinocandins. Hsp90's role in echinocandin resistance has therapeutic potential given that genetic compromise of C. albicans HSP90 expression enhanced the efficacy of an echinocandin in a murine model of disseminated candidiasis. Our results identify the first Hsp90 client protein in C. albicans, establish an entirely new role for Hsp90 in mediating resistance to echinocandins, and demonstrate that targeting Hsp90 provides a promising therapeutic strategy for the treatment of life-threatening fungal disease.
Overview
CoChat Summary
## TL;DR
Hsp90 is required for *Candida albicans* tolerance to echinocandins, and this effect depends largely on calcineurin. Genetic or pharmacological impairment of Hsp90 or calcineurin made micafungin more effective in vitro and in a murine disseminated infection model.
## Key findings
- In antifungal susceptibility and spotting assays, inhibiting Hsp90 with geldanamycin (GdA) or radicicol (RAD) “dramatically enhanced” sensitivity to micafungin (MF) in two strains, and comparable effects were seen with caspofungin (CS).
- Compromising Hsp90 function made the tetO-HSP90/hsp90Δ strain hypersensitive to MF even without tetracycline, and restoring a wild-type HSP90 allele complemented both the reduced growth rate and MF hypersensitivity.
- Inhibiting calcineurin with cyclosporin A (CsA) or FK506 abolished MF tolerance; deleting CNA1 or CNB1 also abrogated MF tolerance, while CRZ1 deletion caused only a partial loss of MF tolerance.
- In the murine model, mice infected with the tetO-HSP90/hsp90Δ strain had significantly reduced kidney fungal burden than mice infected with wild-type HSP90 strain (P<0.05), and MF further reduced fungal burden in the tetO-HSP90/hsp90Δ group (P<0.001).
## Methods
- The study combined pharmacological inhibition (GdA, RAD, CsA, FK506) and genetic perturbation (HSP90, CNA1, CNB1, CRZ1 mutants; tetO-HSP90/hsp90Δ; MAL2p-HSP90/hsp90Δ) in *C. albicans* and *S. cerevisiae*.
- Antifungal tolerance was measured using modified broth microdilution MIC assays, checkerboard synergy assays, and spotting assays on liquid and solid media with MF and CS.
- Mechanistic tests included β-galactosidase reporter assays for calcineurin activation, co-immunoprecipitation of tagged Hsp90 and Cna1, immunoblotting for protein levels, and a tail-vein murine disseminated candidiasis model with kidney CFU readout.
## Limitations
- The paper explicitly notes that the basis for the different responses with micafungin and caspofungin on solid medium is unclear, and the response with anidulafungin “remains to be determined.”
- The authors state that synergy between Hsp90/calcineurin inhibitors and MF was not observed for all echinocandin-resistant clinical isolates tested; of 14 FKS1 mutants, synergy was observed for 8.
- Evidence on cidality was limited by MF-induced clumping, which made CFU counts inaccurate in the echinocandin killing assay; this is stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
19 Valid · 3 Not valid · 19 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This antibody also demonstrated synergy with the echinocandin caspofungin in a murine model [53].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [53] S Hodgetts, 2008, Efungumab and caspofungin: pre-clinical data supporting synergy., J Antimicrob Chemother source
The Introduction identifies efungumab as a human recombinant antibody fragment against Hsp90. The Abstract reports a statistically significant improvement with efungumab plus caspofungin in mice infected with fluconazole-resistant C. albicans, supporting the claimed synergy in a murine model. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Current Hsp90 inhibitors that are well-tolerated in humans as anti-cancer agents exhibit toxicity in the mouse model in the context of an acute fungal infection [22].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [22] LE Cowen, 2009, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease., Proc Natl Acad Sci U S A source
The Discussion states that Hsp90 inhibitors in clinical development as anticancer agents are well tolerated in humans. It also reports significant toxicity with two structurally unrelated Hsp90 inhibitors in a mouse model of acute disseminated C. albicans infection. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, in an invertebrate model of fungal pathogenesis, these pharmacological inhibitors of Hsp90 function enhance the efficacy of the two most widely deployed classes of antifungal drugs, azoles and echinocandins, against the two leading fungal pathogens of humans, Candida albicans and Aspergillus fumigatus [22].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [22] LE Cowen, 2009, Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease., Proc Natl Acad Sci U S A source
The Abstract describes improved efficacy of fluconazole plus Hsp90 inhibitors against C. albicans in Galleria mellonella larvae, and improved larval survival with an Hsp90 inhibitor plus caspofungin against A. fumigatus. The Discussion likewise reports that combination therapy rescued lethal infections with both fungi in this invertebrate host. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This recombinant antibody had therapeutic benefits in a clinical trial in combination with amphotericin B, which targets ergosterol [52].”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Discussion
What the sources say
- Supportedcites [52] J Pachl, 2006, A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis., Clin Infect Dis source
The Abstract identifies Mycograb as a recombinant antibody against fungal heat shock protein 90 and reports better treatment responses when it was combined with lipid-associated amphotericin B than when amphotericin B was given with placebo. The Discussion likewise describes improved clinical and mycological resolution. These passages support the claimed therapeutic benefit in the clinical trial. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with previous findings [23], we confirmed that Hsp90 and calcineurin physically interact in S. cerevisiae (Figure 9A), as they do in C. albicans (Figure 4).”
§ Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin > Results > Divergence of Hsp90 and calcineurin's role in echinocandin tolerance in S. cerevisiae
What the sources say
- Supportedcites [23] J Imai, 2000, Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin., Mol Cell Biol source
The Abstract reports that Hsc82, a yeast HSP90 homologue, coimmunoprecipitated with the calcineurin catalytic subunit Cna2 in Saccharomyces cerevisiae cells under normal conditions. The Discussion also says coimmunoprecipitation experiments revealed complexes of Cna2 with Hsp82 and Hsc82, supporting the attributed physical interaction. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
56 more claims · 1 with their cited sources checked
Create a free account to see all 116 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46].”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In C. albicans, key client proteins of Hsp90 include the Ca2+-calmodulin-activated protein phosphatase calcineurin, and multiple members of the PKC-MAPK cell wall integrity cascade (Pkc1, Bck1, Mkk2 and Mkc1)75–78.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, Hsp90 inhibition blocks the activation of calcineurin-dependent stress responses and PKC signalling, abrogating tolerance and resistance to the azole and echinocandin drugs76,78.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hsp90 depletion phenocopies the azole sensitivity of calcineurin and protein kinase C mutants96,101.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In Candida albicans and Aspergillus fumigatus, role of Hsp90 in echinocandin resistance has been well established [10].”
From Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans (2017) · cites this paper as [10]
Experimental — accuracy not yet measured
26 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“and are responsible for a broad spectrum of disease [1,2].”
BackgroundGlobal analysis of protein expression in yeast
Ghaemmaghami, S., Huh, W.-K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O'Shea, E. K., & Weissman, J. S. (2003) · Nature · doi:10.1038/nature02046 · Cited by 3,750 · cited 1×
“cerevisiae [36].”
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304 · cited 1×
“fumigatus is the principal causal agent of invasive aspergillosis with alarming mortality rates up to 90% that still remain at 40% with the best current treatment options [25,26].”
BackgroundPratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483 · cited 1×
“Hsp90 is an essential chaperone that regulates the form and function of many key signal transducers [17–19].”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444 · cited 1×
“[32,33].”
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103 · cited 1×
“Hsp90 is an essential chaperone that regulates the form and function of many key signal transducers [17–19].”
BackgroundRoles of heat-shock proteins in innate and adaptive immunity.
Srivastava, P. (2002) · Nature reviews. Immunology · doi:10.1038/nri749 · Cited by 1,069 · cited 1×
“Consistent with this thinking, heat-shock proteins are immunodominant antigens for the recognition of many pathogens and play a central role in mediating both innate and adaptive immune responses [54,55].”
BackgroundRoe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“[32,33].”
Zhao, R., Davey, M., Hsu, Y.-C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., et al. (2005) · Cell · doi:10.1016/j.cell.2004.12.024 · Cited by 819 · cited 2×
“cerevisiae [24], while to date not a single Hsp90 client protein has been characterized in C.”
BackgroundZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 1×
“[2,3].”
Cited by
Items 101–200 of 364
Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2
Caplan, T., Lorente-Macías, Á., Stogios, P. J., Evdokimova, E., Hyde, S., Wellington, M. A., Liston, S., Iyer, K. R., Puumala, E., Shekhar-Guturja, T., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.008 · Cited by 57
“Targeting Hsp90 with pharmacological inhibitors such as geldanamycin abrogates resistance to echinocandins and azoles (Cowen and Lindquist, 2005; Singh et al., 2009), and genetic compromise of Hsp90 enhances azole efficacy in a mouse model of disseminated candidiasis (Cowen et al.”
BackgroundSelf-citationThe Clinical Importance of Fungal Biofilms
Ramage, G., & Williams, C. (2013) · Advances in applied microbiology · doi:10.1016/b978-0-12-407673-0.00002-3 · Cited by 62
Polvi, E. J., Averette, A. F., Lee, S. C., Kim, T., Bahn, Y.-S., Veri, A. O., Robbins, N., Heitman, J., & Cowen, L. E. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006350 · Cited by 52
Self-citationKosawang, C., Karlsson, M., Jensen, D. F., Dilokpimol, A., & Collinge, D. B. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-55 · Cited by 61
“Hsp70 and Hsp90 transcripts often accumulate following exposure to biotic and abiotic stresses in several organisms [33,36,37].”
BackgroundHeat shock protein 90 from neglected protozoan parasites
Roy, N., Nageshan, R. K., Ranade, S., & Tatu, U. S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.12.003 · Cited by 55
“An infectious disease causing yeast, namely Candida albicans provides yet another example of exploitation of Hsp90 in disease pathogenesis [30,31].”
BackgroundKim, J., Cho, Y.-J., Do, E., Choi, J., Hu, G., Cadieux, B., Chun, J., Lee, Y., Kronstad, J. W., & Jung, W. H. (2012) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2012.08.006 · Cited by 53
Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 66
“However, incompetence in the Hsp90 function leads to resistance development in fungi against the azole and echinocandin classes [146].”
BackgroundLee, K. K., Kubo, K., Abdelaziz, J. A., Cunningham, I., de Silva Dantas, A., Chen, X., Okada, H., Ohya, Y., & Gow, N. A. R. (2018) · The Cell Surface · doi:10.1016/j.tcsw.2018.09.001 · Cited by 52
Loiko, V., & Wagener, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01690-16 · Cited by 51
Veri, A. O., Miao, Z., Shapiro, R. S., Tebbji, F., O’Meara, T. R., Kim, S. H., Colazo, J., Tan, K., Vyas, V. K., Whiteway, M., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007270 · Cited by 51
Self-citationPais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 51
Shapiro, R. S., & Cowen, L. E. (2010) · Virulence · doi:10.4161/viru.1.1.10320 · Cited by 50
Self-citationRoles of Hsp90 in Candida albicans morphogenesis and virulence
Robbins, N., & Cowen, L. E. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102351 · Cited by 58
Self-citationO’Meara, T. R., O’Meara, M. J., Polvi, E. J., Pourhaghighi, M. R., Liston, S. D., Lin, Z.-Y., Veri, A. O., Emili, A., Gingras, A.-C., & Cowen, L. E. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000358 · Cited by 49
Self-citationPost-Translational Modifications Drive Success and Failure of Fungal–Host Interactions
Retanal, C., Ball, B., & Geddes‐McAlister, J. (2021) · Journal of Fungi · doi:10.3390/jof7020124 · Cited by 56
O'Meara, T. R., & Cowen, L. E. (2014) · Cellular Microbiology · doi:10.1111/cmi.12266 · Cited by 48
“The interactions between C. albicans Hsp90 and calcineurin follow a similar pattern, with co-immunoprecipitation experiments revealing physical interactions between CaHsp90 and calcineurin (Singh et al., 2009).”
BackgroundInfluentialSelf-citationCalcium-calcineurin signaling pathway in Candida albicans: A potential drug target
Li, W., Shrivastava, M., Lu, H., & Jiang, Y. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126786 · Cited by 47
Azole resistance in Aspergillus fumigatus- comprehensive review
Dladla, M., Gyzenhout, M., Marais, G. J., & Ghosh, S. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-04026-z · Cited by 50
“Through various studies, a compromised Hsp90 function in fungi such as Candida albicans and A. fumigatus has been shown to lessen the development of resistance to azoles and echino-candins (Cowen and Lindquist 2005 ; Cowen et al. 2009; Singh et al. 2009 ; Lamoth et al. 2014 ).”
Harren, K., Schumacher, J., & Tudzynski, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041761 · Cited by 56
“albicans it has also been shown that CN is a key mediator of Hsp90-dependent azole resistance [6].”
BackgroundRodríguez-Cabán, J. L., González-Velázquez, W., Pérez-Sánchez, L., Gonzalez-Mendez, R. R., & Valle, N. R.-D. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-162 · Cited by 48
Progress and prospects for targeting Hsp90 to treat fungal infections
VERI, A., & COWEN, L. E. (2014) · Parasitology · doi:10.1017/s0031182013002072 · Cited by 43
“In C. albicans, the first Hsp90 client protein identified was calcineurin (Cowen and Lindquist, 2005; Cowen et al. 2006; Singh et al. 2009), a serine threonine protein phosphatase and key regulator of resistance to azoles and echinocandins (Cruz et al. 2002; Sanglard et al. 2003; Singh et al. 2009).”
BackgroundInfluentialSelf-citationLi, X., Robbins, N., O'Meara, T. R., & Cowen, L. E. (2017) · Molecular Microbiology · doi:10.1111/mmi.13578 · Cited by 43
“Antifungal tolerance and resistance were determined in flat bottom, 96-well microtiter plates using a modified broth microdilution protocol as described (Singh et al., 2009; LaFayette et al., 2010).”
BackgroundMethodInfluentialSelf-citationTargeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
Shahinas, D., Folefoc, A., & Pillai, D. R. (2013) · Pathogens · doi:10.3390/pathogens2010033 · Cited by 56
O’Meara, T. R., Veri, A. O., Polvi, E. J., Li, X., Valaei, S. F., Diezmann, S., & Cowen, L. E. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006142 · Cited by 42
Self-citationEmerging Mechanisms of Drug Resistance in Candida albicans
Prasad, R., Nair, R., & Banerjee, A. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_6 · Cited by 45
Chen, S. C.-A., Lewis, R. E., & Kontoyiannis, D. P. (2011) · Virulence · doi:10.4161/viru.2.4.16764 · Cited by 41
Garnaud, C., García-Oliver, E., Wang, Y., Maubon, D., Bailly, S., Despinasse, Q., Champleboux, M., Govin, J., & Cornet, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01785-17 · Cited by 41
“The implication of Hsp90 in antifungal tolerance is known to be mediated by at least two client proteins: calcineurin (Cmp1) and Mkc1 (11, 18, 19).”
BackgroundInfluentialPianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
“Caspofungin MICs for Screen Hits Within the list of sensitive mutants, we identified multiple biological processes that seem to be important for caspofungin tolerance based on gene ontology analysis (full GO analysis Table S4) (Stajich et al. 2012).”
BackgroundPitarch, A., Nombela, C., & Gil, C. (2014) · Journal of Proteome Research · doi:10.1021/pr500681x · Cited by 46
Potential Microbiological Effects of Higher Dosing of Echinocandins
Steinbach, W. J., Lamoth, F., & Juvvadi, P. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ725 · Cited by 41
Robbins, N., Spitzer, M., Wang, W., Waglechner, N., Patel, D. J., O’Brien, J. S., Ejim, L., Ejim, O., Tyers, M., & Wright, G. D. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.08.015 · Cited by 41
“MIC tests and checkerboard assays were performed in U-bottom, 96-well microtiter plates (Thermo Fisher Scientific) using a modified broth microdilution protocol as described previously (Singh et al., 2009).”
MethodSelf-citationLuo, D., Wu, Y., Liu, J., Zhou, Q., Liu, W., Wang, Y., Yang, Q., Wang, Z., & Liu, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010047 · Cited by 41
“Furthermore, there is much evidence concerning the implications of a large number of genes encoding phenylalanine ammonia-lyase (PAL), β-1,3-glucanase (GLU) and heat shock protein 90 (HSP90) are believed to be involved in biotic stress responses and resistances in many plant species [69,70].”
BackgroundNovel Antifungal Agents and Their Activity against Aspergillus Species
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040213 · Cited by 51
Efg1 Controls Caspofungin-Induced Cell Aggregation of Candida albicans through the Adhesin Als1
Gregori, C., Glaser, W., Frohner, I. E., Reinoso-Martín, C., Rupp, S., Schüller, C., & Kuchler, K. (2011) · Eukaryotic Cell · doi:10.1128/ec.05187-11 · Cited by 39
“albicans cells in the presence of micafungin (48).”
BackgroundFeng, Y., Lu, H., Whiteway, M., & Jiang, Y. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.019 · Cited by 40
Yu, Q., Zhang, B., Yang, B., Chen, J., Wang, H., Jia, C., Ding, X., Xu, N., Dong, Y., Zhang, B., et al. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.09.011 · Cited by 42
A Purine Analog Synergizes with Chloroquine (CQ) by Targeting Plasmodium falciparum Hsp90 (PfHsp90)
Shahinas, D., Folefoc, A., Taldone, T., Chiosis, G., Crandall, I., & Pillai, D. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075446 · Cited by 41
“Several studies indicate that Hsp90 clients are essential proteins within abnormal cells [1,3,9,12,15,16].”
BackgroundIyer, K. R., Whitesell, L. J., Porco, J. A. J., Henkel, T. O., Brown, L. E., Robbins, N., & Cowen, L. E. (2020) · mBio · doi:10.1128/mbio.03329-19 · Cited by 48
“Spotting onto drug-free medium was performed to evaluate cidality as previously described (69).”
Self-citationMarcyk, P. T., LeBlanc, E. V., Kuntz, D. A., Xue, A., Ortiz, F., Trilles, R., Bengtson, S., Kenney, T. M. G., Huang, D. S., Robbins, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01777 · Cited by 40
Self-citationSystematic Analysis of the Lysine Acetylome in Candida albicans
Zhou, X., Qian, G., Yi, X., Li, X., & Liu, W. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00052 · Cited by 39
On the Roles of Calcineurin in Fungal Growth and Pathogenesis
Chen, Y.-L., Kozubowski, L., Cardenas, M. E., & Heitman, J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0027-5 · Cited by 39
Shirazi, F., & Kontoyiannis, D. P. (2013) · Eukaryotic Cell · doi:10.1128/ec.00138-13 · Cited by 39
Yang, Y. Y., Xie, P., Li, Y., Bi, Y., & Prusky, D. (2022) · Journal of Fungi · doi:10.3390/jof8101082 · Cited by 43
Dai, B., Wang, Y., Li, D., Xu, Y., Liang, R., Zhao, L., Cao, Y., Jia, J., & Jiang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045109 · Cited by 37
“Based on previous publications [27,28,30], calcineurin was assumed to be downstream of Hsp90 and regulated by Hsp90.”
BackgroundMethodInfluentialSignaling the glycoshield: Maintenance of the Candida albicans cell wall
Ernst, J. F., & Plá, J. (2011) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2011.04.003 · Cited by 43
Multifactorial Mechanisms of Tolerance to Ketoconazole in Candida albicans
Xu, Y., Lu, H., Zhu, S., Li, W.-Q., Jiang, Y.-Y., Berman, J., & Yang, F. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00321-21 · Cited by 35
“effector Crz1 plays a partial role (40, 41).”
BackgroundKlippel, N., Cui, S., Groebe, L., & Bilitewski, U. (2010) · Microbiology · doi:10.1099/mic.0.040006-0 · Cited by 37
Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options
Amann, V., Kissmann, A., Firacative, C., & Rosenau, F. (2025) · Pharmaceuticals · doi:10.3390/ph18040460 · Cited by 48
“The reasons for high MICs include an increase in the chitin content of the cell wall [273,274] or mutations in the genes coding for Fks1p, the target of echinocandin treatment [256,272,275].”
In Vitro Study of Sequential Fluconazole and Caspofungin Treatment against Candida albicans Biofilms
Sarkar, S., Uppuluri, P., Pierce, C. G., & Lopez-Ribot, J. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01745-13 · Cited by 41
“albicans mutant strain lacking the catalytic subunit of calcineurin ( cna1 cna1) (19) in our sequential checkerboard antifungal drug assay.”
BackgroundRocha, M. C., Minari, K., Fabri, J. H. T. M., Kerkaert, J. D., Gava, L. M., da Cunha, A. F., Cramer, R. A., Borges, J. C., & Malavazi, I. (2020) · Cellular Microbiology · doi:10.1111/cmi.13273 · Cited by 43
“…have shown that when Hsp90 function is compromised, the rapid evolution of resistance to azoles and echinocandins in fungal pathogens such as Candida albicans and A. fumigatus is abrogated (Cowen & Lindquist, 2005; Cowen et al., 2009; Lamoth, Juvvadi, Gehrke, et al., 2014; Singh et al., 2009).”
BackgroundSmall heat shock proteins (HSP12, HSP20 and HSP30) play a role inUstilago maydispathogenesis
Ghosh, A. S. (2014) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12605 · Cited by 40
“Other reports are also available showing the involvement of major heat shock protein HSP 90 in the stress response and pathogenesis of fungi such as Saccharomyces cerevisiae, Candida albicans and Aspergillus fumigatus (Singh et al., 2009; Robbins et al., 2011, 2012; Lamoth et al., 2012).”
BackgroundAn insight into new strategies to combat antifungal drug resistance
Zheng, Y., Ma, Y., Ding, Y., Chen, X., & Gao, G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s185833 · Cited by 38
“14 Pharmacological inhibition of Hsp90 with geldanamycin reduces caspofungin resistance of an A. fumigatus clinical isolate.”
Potentiation of Azole Antifungals by 2-Adamantanamine
LaFleur, M. D., Sun, L., Lister, I., Keating, J., Nantel, A., Long, L., Ghannoum, M., North, J., Lee, R. E., Coleman, K., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00294-13 · Cited by 35
“Synergy between cyclosporine or radicicol and the azoles occurs through inhibition of calcineurin, but AC17 did not inhibit calcineurin according to a UTR2lacZ reporter construct (data not shown) (22).”
BackgroundDiscovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma
Liu, Z., Li, H., He, L., Xiang, Y., Tian, C., Li, C., Tan, P., Ji, J., Tian, Y., Du, L., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.009 · Cited by 37
“Given that calcineurin is one of the client protein of HSP90 (Singh et al., 2009) and YZ129 directly inhibited HSP90, we reasoned that YZ129 might block the chaperon activity of HSP90 to render calcineurin more unstable with concomitant loss of its catalytic activity, thereby leading to the apparent suppression on NFA…”
BackgroundFay, A., Philip, J., Saha, P., Hendrickson, R. C., Glickman, M. S., & Burns-Huang, K. E. (2021) · mBio · doi:10.1128/mbio.00123-21 · Cited by 40
“In the pathogenic fungus Candida albicans, Hsp90 was shown to play a role in AMR to the azoles (6) and the echinocandins (53); in E.”
BackgroundMount, H. O., Revie, N. M., Todd, R. T., Anstett, K., Collins, C., Costanzo, M., Boone, C., Robbins, N., Selmecki, A., & Cowen, L. E. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007319 · Cited by 34
Self-citationEvolutionary Dynamics of Candida albicans during In Vitro Evolution
Huang, M., McClellan, M., Berman, J., & Kao, K. C. (2011) · Eukaryotic Cell · doi:10.1128/ec.05168-11 · Cited by 34
“The mechanisms of resistance to azole drugs have been studied extensively (18, 19, 21, 27, 28, 32, 36, 37, 40, 42, 43).”
BackgroundHeat shock proteins and the calcineurin-crz1 signaling regulate stress responses in fungi
Roy, A., & Tamuli, R. (2022) · Archives of Microbiology · doi:10.1007/s00203-022-02833-w · Cited by 40
“A co-immunoprecipitation study showed the interaction of Hsp90 and calcineurin (Singh et al. 2009), and inhibition of Hsp90 results in a decrease in the expression of calcineurin in C.”
BackgroundResistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 37
AFM combined to ATR-FTIR reveals Candida cell wall changes under caspofungin treatment
Quilès, F., Accoceberry, I., Couzigou, C., Francius, G., Noël, T., & El‐Kirat‐Chatel, S. (2017) · Nanoscale · doi:10.1039/c7nr02170d · Cited by 36
Structure-guided approaches to targeting stress responses in human fungal pathogens
LeBlanc, E. V., Polvi, E. J., Veri, A. O., Privé, G. G., & Cowen, L. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013731 · Cited by 36
“Fungal calcineurin is also an Hsp90 client protein, requiring Hsp90 for stability and functioning as a key mediator of Hsp90-dependent drug resistance (68, 88).”
BackgroundSelf-citationHeat Shock Proteins in Dermatophytes: Current Advances and Perspectives
Martinez-Rossi, N. M., Jacob, T. R., Sanches, P. R., Peres, N. T. A., Lang, E. A. S., Martins, M. P., & Rossi, A. (2015) · Current Genomics · doi:10.2174/1389202917666151116212437 · Cited by 34
“albicans to two major classes of antifungals, the azoles and echinocandins [21, 134, 135].”
BackgroundChen, S., Xia, J., Li, C., Zuo, L., & Wei, X. (2018) · BMC Microbiology · doi:10.1186/s12866-018-1344-z · Cited by 34
Chaperone Networks in Fungal Pathogens of Humans
Horianopoulos, L. C., & Kronstad, J. W. (2021) · Journal of Fungi · doi:10.3390/jof7030209 · Cited by 34
“albicans, Hsp90 plays important roles in temperature-dependent morphological changes at 37 ◦C as well as in contributing to tolerance against the echinocandins [24,25].”
BackgroundLamoth, F., Juvvadi, P. R., Soderblom, E. J., Moseley, M. A., & Steinbach, W. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00946-15 · Cited by 32
Wang, H., Ji, Z., Feng, Y., Yan, T., Cao, Y., Lu, H., & Jiang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1101553 · Cited by 30
“Hsp90 is an important molecular chaperone that regulates fungal drug resistance via physically interacts with the catalytic subunit of calcineurin and Mkc1 and maintains their stable conformations (Cowen, 2009; Singh et al., 2009; LaFayette et al., 2010).”
BackgroundRomán, E., Alonso-Monge, R., Miranda, A., & Pla, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133476 · Cited by 31
Hossain, S., Veri, A. O., & Cowen, L. E. (2020) · mBio · doi:10.1128/mbio.00290-20 · Cited by 31
Self-citationCombinatorial drug approaches to tackleCandida albicansbiofilms
Cremer, K. D., Staes, I., Delattin, N., Cammue, B. P. A., Thevissen, K., & Brucker, K. D. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1056162 · Cited by 35
“Another related promising target for combination therapy is the chaperone protein Hsp90 which is involved in Candida biofilm resistance to several antifungal compounds, at least partly in a calcineurin-dependent manner [95,96].”
BackgroundLu, H., Li, W., Whiteway, M., Wang, H., Zhu, S., Ji, Z., Feng, Y., Yan, L., Fang, T., Li, L., et al. (2023) · mBio · doi:10.1128/mbio.02639-22 · Cited by 30
The relevance of heat shock regulation in fungal pathogens of humans
Brown, A. J. P., Leach, M. D., & Nicholls, S. (2010) · Virulence · doi:10.4161/viru.1.4.12364 · Cited by 30
Chaturvedi, A. K., Weintraub, S. T., Lopez-Ribot, J. L., & Wormley, F. L. (2013) · PROTEOMICS · doi:10.1002/pmic.201300213 · Cited by 32
Ebrahimi-Shaghaghi, F., Noormohammadi, Z., Atyabi, S.-M., & Razzaghi‐Abyaneh, M. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108772 · Cited by 29
Yin, W., Wu, T., Liu, L., Jiang, H., Zhang, Y., Cui, H., Sun, Y., Qin, Q., Sun, Y., Gao, Z., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01991 · Cited by 36
Sah, S. K., Hayes, J. J., & Rustchenko, E. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009564 · Cited by 26
“The right arm of Ch5 carries two genes, MID1 and CNB1, which encode positive regulators of ECN susceptibility [34,35].”
BackgroundUnderstanding of the Hsp90 molecular chaperone reaches new heights
Vaughan, C. K., Neckers, L., & Piper, P. W. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1210-1400 · Cited by 33
Future therapies targeted towards eliminatingCandidabiofilms and associated infections
Bandara, N., Matsubara, V. H., & Samaranayake, L. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1268530 · Cited by 39
Iyer, K. R., Li, S. C., Revie, N. M., Lou, J. W., Duncan, D., Fallah, S., Sánchez, H., Skulska, I., Ušaj, M. M., Safizadeh, H., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.005 · Cited by 31
Self-citationShishodia, S. K., Tiwari, S., Hoda, S., Vijayaraghavan, P., & Shankar, J. (2020) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2020.1711826 · Cited by 33
“In addition, Hsps interacts with other cellular signalling pathways in order to control various physiological activities and virulence in fungi in response to traditional antifungal drugs (Singh et al. 2009; Gong et al. 2017).”
BackgroundZhou, X., Song, N., Li, D., Li, X., & Liu, W. (2021) · mSystems · doi:10.1128/msystems.01316-20 · Cited by 31
A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target
Angel, S. O., Matrajt, M., & Echeverría, P. C. (2013) · Recent Patents on Biotechnology · doi:10.2174/1872208311307010002 · Cited by 27
Ansari, M. A., Fatima, Z., & Hameed, S. (2016) · The Open Microbiology Journal · doi:10.2174/1874285801610010012 · Cited by 30
Tripathi, S., Feng, Q. F., Liu, L., Levin, D. E., Roy, K. K., Doerksen, R. J., Baerson, S. R., Shi, X., Pan, X., Xu, W., et al. (2020) · mSphere · doi:10.1128/msphere.00818-19 · Cited by 29
“albicans that was activated by the echinocandin micafungin (48).”
InfluentialCaspofungin-induced β(1,3)-glucan exposure in Candida albicans is driven by increased chitin levels
Wagner, A. S., Lumsdaine, S. W., Mangrum, M. M., & Reynolds, T. B. (2023) · mBio · doi:10.1128/mbio.00074-23 · Cited by 26
Chen, Y., Wu, X., Xu, C., Huang, J., Zhang, L., Qiu, P., Zheng, D., Chen, W., & Zhang, S. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5614 · Cited by 36
“Under neutrophil‑derived ROS stress, HSP90 stabilizes calcineurin, promoting hyphal morphogenesis and escape from phagolysosomal killing (167).”
Arita, G. S., Faria, D. R., Capoci, I. R. G., Kioshima, É. S., Mendonca, P., & Svidzinski, T. I. E. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.126996 · Cited by 25
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 27
Self-citationDumeaux, V., Massahi, S., Bettauer, V., Mottola, A., Dukovny, A., Khurdia, S. S., Costa, A. C. B. P., Omran, R. P., Simpson, S., Xie, J. L., et al. (2023) · eLife · doi:10.7554/elife.81406 · Cited by 25
Hsp70 and Hsp90 post-translational modifications and translating the chaperone code
Backe, S. J., Heritz, J. A., & Mollapour, M. (2025) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2025.100118 · Cited by 33
Old and new strategies in therapy and diagnosis against fungal infections
Vanzolini, T., & Magnani, M. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12884-8 · Cited by 31
“Moreover, the impaired activation of MAPK-Mkc1 decreased the resistance to ergosterol bio-synthesis inhibitors opening the doors to potential upstream agents able to deplete Mkc1 or, in a similar way, Cek1 and Hog1 (Singh et al. 2009; LaFayette et al. 2010).”
BackgroundInfluentialHsp21 Potentiates Antifungal Drug Tolerance in Candida albicans
Mayer, F. L., Wilson, D., & Hube, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060417 · Cited by 26
“An important client protein chaperoned by Hsp90 is the protein phosphatase calcineurin [14,16].”
BackgroundCha, H., Won, D., Kang, S., Kim, E.-S., Lee, K.-A., Lee, W.-J., Lee, K.-T., & Bahn, Y.-S. (2025) · PLOS Pathogens · doi:10.1371/journal.ppat.1013363 · Cited by 24
“This phenotype is highly unusual and contrasts with other fungal species, such as C. albicans and C. glabrata , where both calcineurin and Crz1 are required for echinocandin resistance [10,33].”
The role of gene copy number variation in antimicrobial resistance in human fungal pathogens
Jay, A., Jordan, D., Gerstein, A. C., & Landry, C. R. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00072-1 · Cited by 30
New antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 53
Wang, X. (2021) · Infectious diseases · doi:10.5772/intechopen.87410 · Cited by 22
The Effects of an Hsp90 Inhibitor on the Paradoxical Effect
Kaneko, Y., Ohno, H., Imamura, Y., Kohno, S., & Miyazaki, Y. (2009) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2009.392 · Cited by 23
“393 fungicidal effects of MFG (10, 11 ). Their latter finding might be related to our results.”
ResultFungal echinocandin resistance
Munro, C. A. (2010) · F1000 Biology Reports · doi:10.3410/b2-66 · Cited by 30
“The chaperone protein Hsp90, acting through its client protein calcineurin, has also been implicated in the regulation of echinocandin resistance [22].”
BackgroundMatos, T. G. F., Morais, F. V., & de Campos, C. B. L. (2012) · Medical Mycology · doi:10.3109/13693786.2012.725481 · Cited by 23
Liu, S., Jiang, L., Miao, H., Lv, Y., Zhang, Q., Ma, M., Duan, W., Huang, Y., & Wei, X. (2022) · Biofouling · doi:10.1080/08927014.2022.2153332 · Cited by 22
Badrane, H., Nguyen, M. H., & Clancy, C. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02711-15 · Cited by 22
Metadata
- Authors
- Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Duke Medical Center (US)
- Corresponding author
- Cowen, Leah E.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-31
- Volume
- 5
- Issue
- 7
- Pages
- e1000532
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2712069
- OpenAlex
- W2087273774
- Cited by
- 362
- References
- 60
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 14 · 2023: 25 · 2022: 24 · 2021: 28 · 2020: 23 · 2019: 18 · 2018: 18 · 2017: 18 · 2016: 20 · 2015: 16 · 2014: 32 · 2013: 25 · 2012: 23
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Burroughs Wellcome Fund
- University of Toronto
- National Institutes of Health
- Canadian Institutes of Health Research (MOP-86452)
- Natural Sciences and Engineering Research Council of Canada
- National Institute of Allergy and Infectious Diseases (AI 73896, R56AI028388, AI28388, R01AI073896, R01AI028388, K08AI065837)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- HSP90, calcineurin, Candida albicans, echinocandin resistance, antifungal resistance, candidiasis, Hsp90 client proteins, Crz1, calcineurin signaling, molecular chaperones, fungal cell wall biosynthesis, HSP90 inhibition, combination antifungal therapy, systemic candidiasis
- MeSH terms
- Micafungin, Analysis of Variance, Animals, Antifungal Agents, Azoles, Candida albicans, Candidiasis, Disease Models, Animal, DNA-Binding Proteins, Fungal Proteins, Male, Stress, Physiological, Transcription Factors, HSP90 Heat-Shock Proteins, Calcineurin, Drug Resistance, Fungal, Mice, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.